Latest news with #DaniellaParra
Yahoo
21-07-2025
- Business
- Yahoo
Harry Upcott Joins Vinson & Elkins to Drive Aviation Finance Expansion in Europe
By Daniella Parra Vinson & Elkins has expanded its global aviation finance practice with the addition of Harry Upcott as a partner in its London office, it said. Upcott brings extensive experience advising on complex aviation and satellite financing, leasing, and M&A deals, and is recognized for his commercially practical approach, the law firm said. 'Vinson & Elkins has a clear focus on building a strong international platform in aviation finance,' Vinson & Elkins Partner Harry Upcott said. 'The firm's integrated capabilities across finance, capital markets and restructuring provide a market-leading platform for supporting clients in this dynamic sector.' READ MORENever Miss an Insight, Our Newsletter Contact: Exec Edge Editor@ Click to follow us on LinkedIn
Yahoo
08-07-2025
- Business
- Yahoo
GameSquare Unveils $100M Ethereum Strategy, Raises $8M in Public Offering
By Daniella Parra GameSquare Holdings (NASDAQ: GAME) said it's launching a crypto-focused treasury strategy backed by a strategic alliance with Dialectic, aiming to generate on-chain yields of 8–14% using Ethereum. The company's board approved up to $100 million in ETH investments over time, it said. GameSquare raised $8 million through a public offering of 8.4 million shares at $0.95 each and proceeds will fund the Ethereum strategy, powered by Dialectic's Medici platform, which leverages AI and risk controls for yield optimization, it said. 'Today's announcement reflects the confidence of a proven group of high-quality investors and leaders in decentralized finance,' said Justin Kenna, CEO of GameSquare. 'We've partnered with one of the world's top crypto investment firms to generate real, on-chain yield while deepening our expertise in decentralized finance, pursuing new revenue streams, and strengthening our balance sheet.' READ MORE GameSquare Steps Up Crypto Strategy Through Dialectic Partnership Register for our weekly newsletter Contact: Exec Edge Editor@ Click to follow us on LinkedIn Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Yahoo
13-06-2025
- Health
- Yahoo
Study Confirms SKY92 Test Improves Multiple Myeloma Risk Assessment
By Daniella Parra A new study published in the British Journal of Haematology confirms that the SKY92 gene expression profiling test significantly enhances risk stratification in multiple myeloma patients, outperforming traditional clinical markers, SkylineDx said. Risk stratification by SKY92 showed significant differences in survival end points, with SKY92 standard-risk patients having a 3-year PFS and OS of 66% and 92% while SKY92 high-risk patients have a 3-year PFS and OS of 39% and 76% respectively, they said. 'This publication confirms years of scientific work and collaboration,' said Jvalini Dwarkasing, PhD, Chief Scientific Officer at SkylineDx. 'The SKY92 signature brings molecular precision to the clinic, giving physicians a powerful tool to reduce uncertainty in a highly complex disease. It's incredibly rewarding to see its positive impact on real-world patient care'. Contact: Exec Edge Editor@
Yahoo
21-05-2025
- Business
- Yahoo
Jeito Capital Leads $65M Series A to Advance Innovations in Reproductive Medicine
By Daniella Parra Jeito Capital said it led a $65 million Series A funding round in ReproNovo, a biotech company focused on reproductive medicine and women's health/. ReproNovo is addressing male and female infertility and uterine health advancing in RPN-001, an oral treatment for male infertility linked to low testosterone and RPN-002, a first-in-class oral treatment for adenomyosis and improving outcomes in assisted reproductive technologies. 'As approximately one in six people worldwide will face infertility issues, we are proud to support ReproNovo, whose commitment to advancing novel therapies in reproductive health aligns well with our focus on accelerating cutting-edge technologies and the commercialization of treatments with transformative benefits for patients,' Ksenija Pavletic, Partner and Chief Commercial Officer at Jeito Capital, said. Contact: Editor@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-05-2025
- Business
- Yahoo
Jeito Capital Leads €132M Series to Advance Phase 3 Trials for Rare Neuro-Metabolic Disorders
By Daniella Parra Jeito Capital said it is leading a €132 million oversubscribed Series B funding round in Azafaros, a clinical-stage biotech company developing treatments for rare lysosomal storage disorders. Azafaros, founded in 2018 and rooted in Dutch academic research, is advancing nizubaglustat, a first-in-class dual-acting drug targeting conditions like Niemann-Pick Type C and GM1/GM2 gangliosidoses, they said. 'Azafaros has the potential to develop new efficient, safe and tolerable therapeutic options for young patients suffering from progressive debilitating and even fatal rare metabolic disorders that generates very high expectations.' said Dr Rafaèle Tordjman, Founder and CEO of Jeito Capital. 'We look forward to supporting the talented Azafaros team with our collective expertise to accelerate its pivotal clinical developments to go faster to patients.' Contact: Exec Edge Editor@
